卡介菌素多糖核酸在治疗糖尿病合并肺结核中的作用

The Effects of BCG Polysaccharide and Nucleic Acid in Treatment of Diabetes Combined with Pulmonary Tuberculosis

目的:探讨卡介菌素多糖核酸(斯奇康)在糖尿病合并肺结核治疗中的作用,为糖尿病合并肺结核治疗寻求新的治疗方法。方法:将112例受试者随机分为化疗+斯奇康治疗组(58例)和单纯化疗对照组(54例),观察临床疗效并检测血清中T淋巴细胞亚群和一氧化氮(NO)水平。结果:两组患者痰菌阴转率有显著性差异(P<0.05),斯奇康治疗组CD4+水平明显高于单纯化疗对照组(P<0.05),两组间NO水平有非常显著性差异(P<0.01)。结论:卡介菌素多糖核酸能提高糖尿病合并肺结核患者痰菌阴转率,它在糖尿病合并肺结核治疗中的作用可能是通过释放大量的NO而增强机体的保护性免疫功能。

Objective: To investigate the effects of BCG poly saccharide and nucleic acid( Siqikang) in treatment of diabetes combined with pulmonary tuberculosis, and explore a new access to treat diabetes combined with pulmonary tuberculosis. Methods: 112 patients were grouped randomly into chemotherapy plus Siqikang group (58 cases) and chemotherapy only control group( 54 cases) . Clinical curative effect was observed, levels of serum T- cell and NO was assayed. Results: Sputum negative conversion rates of two groups had significant difference( P <0.05) ; The level of CD4 in Siqikang treated group was significantly higher than that of chemotherapy only control( P <0.05) ; The levels of NO of two groups had significant difference( P< 0.01) . Conclusion: BCG poly saccharide and nucleic acid can increase sputum negative conversion rates of patients of diabetes combined with pulmonary tuberculosis. It may take effects via releasing large quantity of NO thus strengthen protective immunity ability.